Clinical response to a MEK inhibitor in a patient with metastatic melanoma harboring an RAF1 gene rearrangement detected by cancer gene panel testing

J Dermatol. 2021 Jun;48(6):e256-e257. doi: 10.1111/1346-8138.15849. Epub 2021 Mar 25.

Authors

Kenta Nakama¹, Dai Ogata¹, Eiji Nakano², Keita Tsutsui¹, Shunichi Jinnai¹, Kenjiro Namikawa¹, Akira Takahashi¹, Naoya Yamazaki¹

Affiliations

¹ Department of Dermatological Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.

PMID: 33768587
DOI: 10.1111/1346-8138.15849

No abstract available

Publication types

Letter

MeSH terms

Gene Rearrangement
Genes, Neoplasm
Humans
Melanoma* / drug therapy
Melanoma* / genetics
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics

Substances

Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases

Grants and funding

2020-J-3/National Cancer Center Research and Development Fund